Biobanking Market Analysis by Product (Equipment, Consumables, Service, and Software); by Specimen Type (Blood Products, Human Tissue, Nucleic Acids, Cell Lines, Biological Fluids, and Others); by Storage Type (Manual Storage, and Automated Storage); by Application (Regenerative Medicine, Life Science Research, and Clinical Research); and by End-User (Academic Institutions, and Pharma & Biotech Companies) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

Buy Now Report ID: 4602 | Published Date: Feb 16, 2023

Global Biobanking Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global biobanking market is estimated to garner a revenue of ~ USD 90 billion by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~ USD 50 billion in the year 2022. The growth of the market is primarily attributed to the significant propagation in the biotechnology sector across the globe. The biotechnology sector is a science-driven industry that creates healthcare products by using molecular biology and living organisms. For instance, the biotechnology sector in India alone is expected to reach approximately USD 81 billion in 2022, to reach nearly USD 152 billion by 2025, and USD 310 billion by 2030. Furthermore, the proliferation of genomics research activities for various diseases study is another significant factor that is driving the growth of the global biobanking market during the projected period.

Biobanking-Market-scope Get more information on this report:Download Sample PDF 

Biobanks assist in the development of multi-omics biobanks, in which insights from genomes, proteomics, and metabolomics are linked with radiomic data to produce a fresh and personalized technique for disease treatment. The implementation of big data and AI have been transforming the array of biobanks for the more advanced development of precision medicine. For instance, the purpose of precision medicine is to deliver clinicians the ability to determine the best course of action for a patient effectively, and accurately. The precision medicine eco-system, which is constantly evolving, is the answer to the issue. Precision medicine emphasizes the significance of integrating molecular profiling with well-established clinical index values to develop diagnostic, predictive, and therapeutic approaches customized to the requirements of each patient. For the precision medicine ecosystem to be used to its full potential, data must be properly interpreted. The best course of action to be taken for each unique patient group is determined by the precision medicine ecosystem's combination of genomic and clinical data. Moreover, increasing advancement in orthopedic procedures implying stem cells is also anticipated to fuel up the market growth of the global biobanking market over the forecast period.

Get more information on this report: Request Free Sample PDF

Global Biobanking Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 50 Billion

Forecast Year Market Size (2033)

~ USD 90 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Global Biobanking Market: Growth Drivers and Challenges


Growth Drivers

  • Growing Research Activities Associated with Genomics – As per the World Health Organization (WHO), as a result of significant investments made during the COVID-19 pandemic, the percentage of countries capable of carrying out genomic surveillance expanded from 54% to 68% between March 2021 and January 2022.

Genomics research is the study of full genetics along with the complement of an organism. It is generally conducted to prepare personalized medicines and focus on the editing, mapping, structure, function, and evolution of a genome. Furthermore, there has been growing popularity of genomics in cancer care for providing personalized medicines to the patients for the cure. In addition, genomic research can obtain several public targets, such as a reduction in health disparities. Therefore, the surge in genomics research is expected to fuel market growth over the forecast period.

  • Increasing Instances of Umbilical Cord Blood Cell Conservation – For instance, in Japan, approximately 36% of childbirth facilities presently provide umbilical cord blood cell storage to private biobanks, which is an increase from 15% in the past.

  • Escalating Count of Biobanks Globally – For instance, the worldwide number of biobanks reached around 130 by the end of 2018. Hence, the surge in the number of biobanks is expected to enlarge the market size over the forecast period.

  • Rising Cases of Hemophilia and Bleeding Disorders – Hemophilia is a disorder that interrupts the clotting of blood. It is a rare disorder that can develop in humans based on their genetics. For instance, between 2021 to 2022, approximately 200 thousand people were noticed to be living with hemophilia across the globe.


  • Associated High Cost of Storage of Specimen Samples – The process of specimen sample storage in biobanks requires costly equipment, which in turn, makes the entire process of storage expensive. This factor is estimated to hinder the growth of the biobanking market.
  • Deficit in Counselling and Training on Medical Ethics
  • Misconceptions about Biobanking

Market Segmentation

The global biobanking market is segmented and analyzed for demand and supply by specimen type into blood products, human tissue, nucleic acids, cell lines, biological fluids, and others. Out of these sub-segments, the blood products segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the rising demand for the collection of specimens of blood products, the radically increasing the ratio of accidents, and the potentially growing prevalence of several types of hematological disorders across the globe.  For instance, in the United States, one person is diagnosed with leukemia, lymphoma, or myeloma every 4 minutes. Furthermore, in the United States, approximately 189,500 individuals were anticipated to be diagnosed with leukemia, lymphoma, or myeloma in 2021. Furthermore, blood products improve maternal health and child mortality and save millions of lives. 

The global biobanking market is also segmented and analyzed for demand and supply by application into regenerative medicine, life science research, and clinical research. Amongst these segments, the clinical research segment is expected to garner a significant share. In clinical research, biobanking is used for the systematic collection of data on a large scale and tissues for additional research purposes. Clinical research can last for an uncertain period, where biobanks become useful to preserve specimens with 100% quality for a prolonged time. For instance, in FY 2020, the National Institutes of Health were estimated to fund approximately USD 16 billion for clinical research in the United States.

Our in-depth analysis of the global biobanking market includes the following segments:

            By Product

  • Equipment
  • Consumables
  • Service
  • Software

           By Specimen Type

  • Blood Products
  • Human Tissue
  • Nucleic Acids
  • Cell Lines
  • Biological Fluids
  • Others

         By Storage Type

  • Manual Storage
  • Automated Storage


         By Application

  • Regenerative Medicine
  • Life Science Research
  • Clinical Research

         By End-User

  • Academic Institutions
  • Pharma & Biotech Companies

Global Biobanking Market Regional Synopsis


The North American biobanking market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the rising adoption of advanced technology, along with the growing awareness regarding biobanking among the people and research professionals, and the escalating investment in research and development activities in the region. For instance, the 16 largest pharmaceutical firms in the United States invested about USD 140 billion in research and development in 2021, which represents a 43% hike from 2016. Additionally, the surge in stem cell practices in the region to develop solutions for various diseases backed by the ongoing development via stem cell technology in regenerative medicines is further projected to expand the market size during the forecast period. Stem cell technology has become the most important treatment method for multiple diseases such as cancer, rare genetic diseases, diabetes, Alzheimer’s, and others. In the United States, approximately 30 million people suffer from diabetes. However, in 2018, around 25 million people were diagnosed with diabetes in a similar region.


Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Global Biobanking Market

    • UK Biobank Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific Holdings, Inc.
    • Tecan Trading AG
    • Hamilton Bonaduz AG
    • Bay Biosciences LLC.
    • ASKION GmbH
    • Promega Corporation
    • VWR International, LLC.
    • Merck KGaA


In The News

  • Thermo Fisher Scientific Inc. and Qatar Genome Program (QGP), a member of Qatar Foundation, partnered to speed up genomic research and clinical applications of predictive genomics in Qatar to accelerate the benefits of precision medicine across Arab populations worldwide. By combining whole genome sequencing data with an Axiom custom genotyping array for Pan-Arab populations, this partnership aims to advance scientific research and provide insights into conditions such as diabetes, cardiovascular and metabolic disorders, autism, and other genetic disorders.

  • UK Biobank Limited released the Whole Genome Sequencing (WGS) data of 200,000 UK Biobank participants for research use. Through these steps, researchers are estimated to understand the genetic factors of the disease and accelerate advanced drug discovery work.


Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Author Credits:  Radhika Gupta, Shivam Bhutani

Key Questions Answered in the Report

1) What are the major factors driving the growth of the biobanking market?

Ans: Increasing instances of umbilical cord blood cell conservation are the major factors driving the market growth.

2) What would be the CAGR of biobanking market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 – 2033.

3) What are the challenges affecting the biobanking market growth?

Ans: The associated high cost of storage of specimen samples is estimated to be the growth hindering factor for the market expansion.

4) Which region will provide more business opportunities for growth of biobanking market in future?

Ans: The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

5) Who are the major players dominating the biobanking market?

Ans: The major players in the market are Thermo Fisher Scientific Holdings, Inc., Tecan Trading AG, Hamilton Bonaduz AG, Bay Biosciences LLC., ISENET USA LLC, ASKION GmbH, Promega Corporation, VWR International, LLC., Merck KGaA, and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the biobanking market?

Ans: The market is segmented by product, specimen type, storage type, application, end-user, and by region.

8) Which segment captures the largest market size in specimen type segment in the biobanking market?

Ans: The blood products segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

 Request Free Sample Copy